Nexstim Plc · OMXHEX:NXTMH
Nexstim — Biotech Showcase 2015
12 slides from Nexstim's conference presentation, 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Janne Huhtala | CEO | Nexstim Biotech Showcase 2015
Slide 2: Important information
Important information This confidential presentation and the information contained herein is being presented by Nexstim Oyj Should any recipient of this presentation consider an investment in the Company, such recipient must (“Nexstim” or “the Company”). By attending a meeting where this presentatio
Slide 3: Nexstim at a glance
Introduction Nexstim at a glance ● Finnish medtech ● Established in 2000 ● 34 employees ● Offices in US and Germany ● Backed by leading European life-science VCs ● Listed in Nasdaq Helsinki & Stockholm 3
Slide 4: Nexstim – Targeting a paradigm shift in stroke rehabilitation
Introduction Nexstim – Targeting a paradigm shift in stroke rehabilitation Nexstim’s Navigated Nexstim’s NavigatedBrain Therapy® Brain (NBT) Therapy® Targeting Targetingaablockbuster blockbustermarket… market solution (NBT) for for solution stroke rehabilitation stroke rehabilitation (market for pos
Slide 5: Technology platform applied in stroke and brain surgery
Introduction Technology platform applied in stroke and brain surgery Novel technology Two products Main uses Status Navigation technology to Stroke rehabilitation –CE marked deliver accurate magnetic Navigated Precise localisation of the –Positive Phase II data pulses to stimulate the Brain correct
Slide 6: NBT for stroke rehabilitation – How it works
Stroke– NBT System NBT for stroke rehabilitation – How it works Problem post stroke: Nexstim’ssolution: Overactive inhibition from the non-damaged side interferes Repeated inhibitory stimulation to non-damaged side when the patient tries to move paralyzed limb restores balance, removing barriers for
Slide 7: Efficacy demonstrated in Phase II trial
Stroke – NBT System Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NBT
Slide 8: Nexstim's unique technology provides distinct benefits
Stroke – NBT System Nexstim’s unique technology provides distinct benefits Integration of TMS and navigation Several distinct benefits Enhanced limb move ● TMS-navigation integration: ● Improved accuracy: Accurate ● Substantially Nexstim combines non-invasive localisation of the target muscle improv
Slide 9: IP position
Patents IP position 60 granted patents 67 pending patents Right to software: Nexstim owns rights to its NBT and NBS Systems’ software developed by it. Creating hurdles for competitors: by e.g. seeking patent protection on different parts of the products and making it more difficult for potential com
Slide 10: Phase III trials - Laying the groundwork for commercialisation
Stroke – NBT System Phase III trials - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites Rehabilitation Institute of Chicago (central site) ● Document ● Establish clinical efficacy of NBT in TIRR Memorial Hermann Hospital (Houston) effects/effi
Slide 11: Highlights in Stroke Rehabilitation (NBT)
Stroke– NBT System Highlights in Stroke Rehabilitation (NBT) – 2.1m strokes each year in the US and Europe Huge unmet need – Stroke is the leading cause of long-term disability in Western world – While current standard treatment of physical/occupational therapy is not very Few effective alternatives
Slide 12: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation